CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN REFRACTORY OR RELAPSED MULTIPLE MYELOMA - A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG)
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Aug 2018
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Bendamustine; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
- 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.